PO.TB07.02 · 肿瘤生物学

APOBEC3C重塑造血干细胞和祖细胞的RNA剪接与自我更新

APOBEC3C rewires RNA splicing and self-renewal in hematopoietic stem and progenitor cells

海报缩略图:APOBEC3C重塑造血干细胞和祖细胞的RNA剪接与自我更新
编号 2202 展板 21 时间 4/20 09:00–12:00 区域 Section 30 主讲 Inge van der Werf, PhD
分会场 Metabolic and Transcriptional Control of Cancer Stem Cell Plasticity
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Inge van der Werf1, Jane Isquith1, Emma Klacking1, Jessica Pham1, Wenxue Ma1, Shuvro P. Nandi2, Rongjie Wu2, Claire Engstrom1, Neha Katragadda1, Anna A. Khachatrian3, Thomas Whisenant2, Ludmil Alexandrov2, Catriona Jamieson1

1Sanford Stem Cell Institute, UC San Diego, La Jolla, CA,2UC San Diego, La Jolla, CA,3Scripps Health, La Jolla, CA

摘要 Abstract

中文摘要
引言 炎症性细胞因子应答的APOBEC3胞嘧啶脱氨酶通过DNA和RNA编辑促进抗病毒防御,而当其失调时则驱动体细胞突变和癌症进展。虽然APOBEC3A和APOBEC3B已被充分研究,但APOBEC3C的作用仍不甚明确。然而,我们最近对骨髓增殖性肿瘤(MPN)来源的造血干细胞和祖细胞(HSPC)进行的全基因组和全转录组分析显示,APOBEC3C在此背景下高表达,提示其在造血中具有特定情境的功能。这一观察促使我们研究APOBEC3C以及其他APOBEC家族成员对HSPC生物学的影响,重点关注它们作为衰老和炎症背景下克隆性造血(CH)和髓系疾病驱动因素的作用。 方法 我们收集了健康脐带血(CB)和老年骨髓(ABM),并用APOBEC3B、C、D、F或G或pCDH慢病毒骨架对照,对免疫磁珠筛选的CD34+细胞进行慢病毒转导。随后,我们进行了全基因组和转录组分析,评估C-to-T DNA突变、C-to-U RNA编辑和差异基因表达。由于在慢病毒转导APOBEC3C后观察到RNA剪接的广泛变化以及CH相关基因表达的广泛变化,我们还分别进行了双荧光剪接报告基因实验、存活和自我更新实验以及体内植入研究。 结果 我们发现APOBEC3C和3F诱导更多DNA突变,而APOBEC3B、3C和3G破坏RNA剪接。我们观察到对造血至关重要的基因差异表达,如ZRSR2、U2AF1和SRSF2,以及差异外显子使用和剪接体通路的富集。此外,我们证明APOBEC3C在ABM HSPC中诱导的转录组效应显著大于CB HSPC。我们观察到差异基因表达增加10倍,包括核糖体基因(RPS19和RPL5)的改变,以及与CH、MPN和骨髓增生异常综合征(MDS)发病机制相关的剪接因子(U2AF1、ZRSR2和SF3B2)的改变。此外,在ABM HSPC中,发现APOBEC3C影响CH相关转录本,包括DNMT3A,增强ADAR1介导的RNA编辑,并提高自我更新能力。与这些发现一致,APOBEC3C在JAK2+ MPN HSPC中升高,而其敲低减少了JAK2+ MPN CD34+的自我更新和ADAR1报告基因活性。 结论 总之,这些发现表明APOBEC3C调控CB来源HSPC中的RNA剪接和C-to-U RNA编辑,在ABM来源HSPC中效应更为显著。在ABM中,这还包括ADAR1p150表达增加和A-to-I编辑升高,结合HSPC扩增增加,可能促进髓系疾病的发病和进展。
查看英文原文 English abstract
Introduction Inflammatory cytokine-responsive APOBEC3 cytosine deaminases promote antiviral defense through DNA and RNA editing and, when deregulated, drive somatic mutations and cancer progression. While APOBEC3A and APOBEC3B are well studied, the role of APOBEC3C remains less defined. However, our recent whole genome and whole transcriptome analyses of myeloproliferative neoplasm (MPN) derived hematopoietic stem and progenitor cells (HSPCs) revealed that APOBEC3C is highly expressed in this context, suggesting a context-specific function in hematopoiesis. This observation prompted us to investigate the effects of APOBEC3C, alongside other APOBEC family members, on HSPC biology, with an emphasis on their roles as drivers of clonal hematopoiesis (CH) and myeloid disorders in the context of aging and inflammation. Methods We collected healthy cord blood (CB) and aged bone marrow (ABM), and lentivirally transduced immunomagnetic bead-selected CD34 + cells with APOBEC3B, C, D, F, or G, or pCDH lentiviral backbone controls. Subsequently, we performed whole genome and transcriptome analyses and assessed C-to-T DNA mutations, C-to-U RNA edits and differential gene expression. As widespread changes in RNA splicing where observed as well as widespread changes in expression of genes implicated in CH upon lentiviral transduction of APOBEC3C, we also performed dual fluorescent splicing reporter assays, survival and self-renewal assays, and in vivo engraftment studies, respectively. Results We discovered that APOBEC3C and 3F, induce more DNA mutations, whereas APOBEC3B, 3C and 3G disrupt RNA splicing. We observed differential expression of genes crucial for hematopoiesis, such as ZRSR2, U2AF1, and SRSF2, as well as differential exon usage and enrichment of the spliceosome pathway. Additionally, we demonstrated that APOBEC3C induced substantially greater transcriptomic effects in ABM HSPCs compared to CB HSPCs. We observed a 10-fold increase in differential gene expression, including alterations in ribosomal genes (RPS19 and RPL5), alongside splicing factors (U2AF1, ZRSR2, and SF3B2) implicated in CH, MPN, and myelodysplastic syndrome (MDS) pathogenesis. Moreover, in ABM HSPCs, APOBEC3C was found to affect CH-associated transcripts, including DNMT3A, enhance ADAR1-mediated RNA editing, and increase self-renewal capacity. Consistent with these findings, APOBEC3C is elevated in JAK2 + MPN HSPCs, while its knockdown reduced JAK2⁺ MPN CD34⁺ self-renewal and ADAR1 reporter activity. Conclusion In conclusion, these findings demonstrate that APOBEC3C modulates RNA splicing and C-to-U RNA editing in CB derived HSPCs, with more pronounced effects in ABM derived HSPCs. In ABM, this also includes increased ADAR1p150 expression and elevated A-to-I editing, which combined with increased HSPC expansion, may contribute to the pathogenesis and progression of myeloid disorders.
利益披露 Disclosure
I. van der Werf, None.. J. Isquith, None.. E. Klacking, None.. J. Pham, None.. W. Ma, None.. S. P. Nandi, None.. R. Wu, None.. C. Engstrom, None.. N. Katragadda, None.. A. A. Khachatrian, None.. T. Whisenant, None. L. Alexandrov, IO9 Other, Co-founder. C. Jamieson, Aspera Biomedicines Other, Co-founder. Impact Biomedicines Other, Co-founder. Forty Seven Inc Other, Royalties.

← 返回 AACR 2026 检索